Carlyle price target lowered to $47 from $50 at BofA
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
The Search For 7% Investment Grade Yields, Part 2: Carlyle And Its Baby Bond
The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...
Carlyle's profit misses estimates as private equity business weighs
Carlyle Group's distributable fourth-quarter earnings missed market expectations on Tuesday, eclipsing a strong growth in the ...
BioPharma Dive1d
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
The Carlyle Group (NASDAQ:CG) Cut to Sell at StockNews.com
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
Carlyle's profit misses estimates on lower proceeds from asset sales
Carlyle Group's distributable earnings for the fourth quarter missed market expectations on Tuesday, overshadowing a strong ...
Carlyle's Savino Expects IPOs to Increase in 2025
Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.